5.13
-0.09(-1.72%)
Currency In USD
| Previous Close | 5.22 |
| Open | 5.26 |
| Day High | 5.32 |
| Day Low | 4.96 |
| 52-Week High | 6.79 |
| 52-Week Low | 0.6 |
| Volume | 757,746 |
| Average Volume | 2.64M |
| Market Cap | 419.76M |
| PE | -10.06 |
| EPS | -0.51 |
| Moving Average 50 Days | 4.45 |
| Moving Average 200 Days | 2.15 |
| Change | -0.09 |
If you invested $1000 in I-Mab (IMAB) since IPO date, it would be worth $410.4 as of October 21, 2025 at a share price of $5.13. Whereas If you bought $1000 worth of I-Mab (IMAB) shares 3 years ago, it would be worth $1,322.16 as of October 21, 2025 at a share price of $5.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
GlobeNewswire Inc.
Oct 16, 2025 8:05 PM GMT
New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwideIntention to pursue a Hong Kong in
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
GlobeNewswire Inc.
Oct 14, 2025 11:00 AM GMT
The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global bio
I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments
GlobeNewswire Inc.
Sep 08, 2025 12:30 PM GMT
Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to followReiterates expectations to repor